Quick Answer
Ultragenyx Pharmaceutical Inc. reported Total Revenue of $673.00 million for fiscal year 2025.
Ultragenyx Pharmaceutical Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $673.00M +20.2% |
$560.00M +29.0% |
$434.00M +19.5% |
$363.33M +3.4% |
$351.41M +29.7% |
$271.03M +161.3% |
| Revenue (ASC 606) | $673.00M +20.2% |
$560.00M +29.0% |
$434.00M +19.5% |
$363.33M +3.4% |
$351.41M +29.7% |
$271.03M +161.3% |
| Net Income | -$575.00M -1.1% |
-$569.00M +6.3% |
-$607.00M +14.2% |
-$707.42M -55.8% |
-$454.02M -143.4% |
-$186.57M +53.7% |
| Diluted EPS | -$5.83 +7.3% |
-$6.29 +23.8% |
-$8.25 +18.5% |
-$10.12 -51.0% |
-$6.70 -118.2% |
-$3.07 |
| Total Assets | $1.53B +1.9% |
$1.50B +0.8% |
$1.49B -3.5% |
$1.55B +1.5% |
$1.52B -13.5% |
$1.76B +55.0% |
| Cash and Equivalents | $421.00M +142.0% |
$174.00M -18.7% |
$214.00M +61.0% |
$132.94M -56.8% |
$307.58M -56.9% |
$713.53M +64.6% |
| Stockholders Equity | -$80.00M -131.4% |
$255.00M -7.3% |
$275.00M -21.9% |
$352.00M -61.8% |
$922.56M -20.1% |
$1.15B +76.6% |
| R&D Expense | $750.00M +7.4% |
$698.00M +7.7% |
$648.00M -8.2% |
$705.79M +42.0% |
$497.15M +20.6% |
$412.08M +15.3% |
| Operating Income | -$535.00M +0.2% |
-$536.00M +5.8% |
-$569.00M +12.3% |
-$648.92M -70.0% |
-$381.74M -15.6% |
-$330.12M +22.2% |
| Shares Outstanding | 96.60M +4.4% |
92.50M +12.4% |
82.32M +17.3% |
70.20M +1.2% |
69.34M +3.8% |
66.82M +15.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $159.93M | +14.7% | -3.9% |
| Revenue (ASC 606) | September 30, 2025 | $159.93M | +14.7% | -3.9% |
| Net Income | September 30, 2025 | -$180.41M | -35.1% | -56.9% |
| Diluted EPS | September 30, 2025 | -$1.81 | -29.3% | -54.7% |
| Total Assets | September 30, 2025 | $1.19B | -22.6% | -8.9% |
| Cash and Equivalents | September 30, 2025 | $202.51M | +34.5% | +14.9% |
| Stockholders Equity | September 30, 2025 | $9.16M | -97.4% | -93.9% |
| R&D Expense | September 30, 2025 | $216.21M | +27.1% | +31.2% |
| Operating Income | September 30, 2025 | -$170.89M | -29.5% | -58.4% |
| Shares Outstanding | September 30, 2025 | 96.44M | +4.5% | +0.1% |
- Ultragenyx Pharmaceutical Inc. reported Total Revenue of $673.00 million for fiscal year 2025.
- Ultragenyx Pharmaceutical Inc. showed an increase of +20.2% in Total Revenue compared to the prior fiscal year.
- Ultragenyx Pharmaceutical Inc. reported Revenue (ASC 606) of $673.00 million for fiscal year 2025.
- Ultragenyx Pharmaceutical Inc. showed an increase of +20.2% in Revenue (ASC 606) compared to the prior fiscal year.
- Ultragenyx Pharmaceutical Inc. reported Net Income of -$575.00 million for fiscal year 2025.
- Ultragenyx Pharmaceutical Inc. showed a decrease of -1.1% in Net Income compared to the prior fiscal year.
- Ultragenyx Pharmaceutical Inc. reported Diluted EPS of $5.83 per share (loss) for fiscal year 2025.
- Ultragenyx Pharmaceutical Inc. showed an increase of +7.3% in Diluted EPS compared to the prior fiscal year.
- Ultragenyx Pharmaceutical Inc. reported Total Assets of $1.53 billion for fiscal year 2025.
- Ultragenyx Pharmaceutical Inc. showed an increase of +1.9% in Total Assets compared to the prior fiscal year.
- Ultragenyx Pharmaceutical Inc. reported Cash and Equivalents of $421.00 million for fiscal year 2025.
- Ultragenyx Pharmaceutical Inc. showed an increase of +142.0% in Cash and Equivalents compared to the prior fiscal year.
- Ultragenyx Pharmaceutical Inc. reported Stockholders Equity of -$80.00 million for fiscal year 2025.
- Ultragenyx Pharmaceutical Inc. showed a decrease of -131.4% in Stockholders Equity compared to the prior fiscal year.
- Ultragenyx Pharmaceutical Inc. reported R&D Expense of $750.00 million for fiscal year 2025.
- Ultragenyx Pharmaceutical Inc. showed an increase of +7.4% in R&D Expense compared to the prior fiscal year.
- Ultragenyx Pharmaceutical Inc. reported Operating Income of -$535.00 million for fiscal year 2025.
- Ultragenyx Pharmaceutical Inc. showed an increase of +0.2% in Operating Income compared to the prior fiscal year.
- Ultragenyx Pharmaceutical Inc. reported Shares Outstanding of 96.60 million shares for fiscal year 2025.
- Ultragenyx Pharmaceutical Inc. showed an increase of +4.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: